Serum IL-23 Levels and Response to Apremilast in Psoriatic Arthritis
Author Information
Author(s): De Santis Maria, Tonutti Antonio, Isailovic Natasa, Motta Francesca, Rivara Radu Marian, Ragusa Rita, Guidelli Giacomo M., Caprioli Marta, Ceribelli Angela, Renna Daniela, Luciano Nicoletta, Selmi Carlo
Primary Institution: Humanitas University and IRCCS Humanitas Research Hospital
Hypothesis
Can serum IL-23 levels predict the response to apremilast in patients with psoriatic arthritis?
Conclusion
Serum IL-23 levels can serve as candidate biomarkers for predicting the response to apremilast in patients with psoriatic arthritis.
Supporting Evidence
- 74% of patients responded to apremilast after 4 months.
- Higher baseline serum IL-23 levels were associated with better treatment response.
- Apremilast reduced IL-23 expression in macrophages.
Takeaway
Doctors can check a blood test for IL-23 to see if a medicine called apremilast will work for people with psoriatic arthritis.
Methodology
Patients with psoriatic arthritis were treated with apremilast, and blood samples were analyzed for cytokine levels and expression before and after treatment.
Potential Biases
Potential bias due to concurrent treatments and the small, non-representative sample size.
Limitations
The small sample size and the predominance of oligoarthritis limit the generalizability of the findings.
Participant Demographics
23 patients with psoriatic arthritis (43% women, median age 56 years) and 20 controls with osteoarthritis.
Statistical Information
P-Value
p = 0.003
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website